NCT03064269 2023-11-29
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
Clinical Trials
79 trialsNCT05747157 2023-11-21
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research
Anhui Provincial Hospital
Phase EARLY_PHASE1 Unknown
NCT05020392 2023-07-25
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3 Unknown
NCT05105867 2023-05-10
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase EARLY_PHASE1 Unknown
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT05654038 2022-12-21
A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05651191 2022-12-14
To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05559450 2022-09-29
Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05480501 2022-07-29
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05379647 2022-05-18
Natural Killer (NK) Cell Therapy for B-Cell Malignancies
Zhejiang University
Phase 1 Unknown
NCT05309213 2022-04-04
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT05262673 2022-03-08
NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL
Shenzhen Geno-Immune Medical Institute
Phase 1 Unknown
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT05049473 2021-09-20
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
PETHEMA Foundation
Phase 2 Unknown
NCT00003337 2021-08-16
Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 3 Unknown
NCT00003338 2021-08-16
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 2/3 Unknown
NCT04289220 2021-05-13
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
Yan'an Affiliated Hospital of Kunming Medical University
Phase 1 Unknown
NCT04653493 2021-03-19
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Sabz Biomedicals
Phase 1 Unknown
NCT04747093 2021-02-10
Induced-T Cell Like NK Cells for B Cell Malignancies
Nanfang Hospital, Southern Medical University
Phase 1/2 Unknown
NCT04740203 2021-02-05
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL
Zhejiang University
Phase 1/2 Unknown
NCT03156101 2021-02-04
A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT04204161 2021-02-04
A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
Shenzhen BinDeBio Ltd.
Phase 1 Unknown
NCT04723901 2021-01-26
CAR-T
Shenzhen University General Hospital
Phase 1/2 Unknown
NCT04626726 2020-11-13
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03559439 2020-11-05
CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
Shanghai Tong Ren Hospital
Phase 1 Unknown
NCT04534634 2020-09-01
Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT04129099 2020-05-28
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Hebei Yanda Ludaopei Hospital
Phase EARLY_PHASE1 Unknown
NCT04264039 2020-02-11
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Xinqiao Hospital of Chongqing
Phase EARLY_PHASE1 Unknown
NCT03638206 2019-12-11
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
Phase 1/2 Unknown
NCT04191941 2019-12-10
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown
NCT04184414 2019-12-03
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04166838 2019-11-18
The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)
Shanghai Longyao Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03599375 2019-02-26
Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia
The First Hospital of Jilin University
Phase 1 Unknown
NCT03854994 2019-02-26
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
Yan'an Affiliated Hospital of Kunming Medical University
Phase 1 Unknown
NCT03825731 2019-01-31
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Hebei Yanda Ludaopei Hospital
Phase EARLY_PHASE1 Unknown
NCT03671460 2018-09-14
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Tianjin Mycure Medical Technology Co., Ltd
Phase 1 Unknown
NCT03574168 2018-06-29
CD19-CAR-T Cells in Patients With R/R B-ALL
Bioceltech Therapeutics, Ltd.
Phase 1 Unknown
NCT03391739 2018-01-05
CCFRRBA
Fujian Medical University
Phase 2/3 Unknown
NCT02924753 2017-12-29
The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Henan Cancer Hospital
Phase 1 Unknown
NCT03321123 2017-10-25
MB-CART19.1 in Patients With R/R ALL
Shanghai Children's Medical Center
Phase 2 Unknown
NCT03263208 2017-10-20
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
Henan Cancer Hospital
Phase 1/2 Unknown
NCT03298828 2017-10-02
CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
Third Military Medical University
Phase 1 Unknown
NCT02585947 2016-12-21
To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma
Seoul National University Hospital
Phase 4 Unknown
NCT02968472 2016-11-18
A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia
The First People's Hospital of Yunnan
Phase 1 Unknown
NCT02134262 2014-11-06
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
Jichi Medical University
Phase 1/2 Unknown
NCT02247609 2014-10-20
4SCAR19273
Peking University
Phase 1/2 Unknown
NCT01279707 2014-07-14
MARALL
Queen Mary University of London
Phase 1/2 Unknown
NCT00084695 2014-01-10
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01016990 2014-01-10
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01307592 2014-01-10
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown